Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2026)

Rani Therapeutics Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $16.3 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 44.57% year-over-year to $16.3 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a 44.57% decrease from a year earlier, with the FY2025 full-year figure at $17.1 million, down 48.38% from the prior year.
• Total Liabilities declined to $16.3 million in Q1 2026 per RANI's latest filing, from $17.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $39.0 million in Q1 2024 and bottomed at $4.7 million in Q1 2022.
• The 5-year median for Total Liabilities is $32.5 million (2023), against an average of $27.3 million.
• Across the five-year window, Total Liabilities soared 1188.75% in 2022 and tumbled 48.38% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $34.0 million in 2022, then decreased by 4.56% to $32.5 million in 2023, then climbed by 2.06% to $33.1 million in 2024, then tumbled by 48.38% to $17.1 million in 2025, then dropped by 4.52% to $16.3 million in 2026.
• Per Business Quant, the three latest RANI Total Liabilities figures stand at $16.3 million (Q1 2026), $17.1 million (Q4 2025), and $22.1 million (Q3 2025).